GlassScriptPhysician profile
Thomas Byrne
NPI 1356416358
$1,287.04
in general payments reported to CMS, 2019-2025
22 companies · $150 in 2025
The $150 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $17.04 · 2021: $350 · 2022: $357 · 2023: $192 · 2024: $91.00 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $453.04 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $96.73 | 2022-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Astrazeneca Pharmaceuticals LP | $81.11 | 2022-2025 | Flumist Quadrivalent, Fasenra |
| Pfizer INC. | $66.06 | 2019-2023 | |
| Corium, LLC | $65.82 | 2022 | |
| Ironshore Pharmaceuticals INC. | $60.32 | 2019-2022 | |
| Alk-Abello, INC | $59.99 | 2021-2022 | |
| Seqirus USA INC | $53.17 | 2025 | Flucelvax |
| Merck Sharp & Dohme LLC | $45.80 | 2022-2025 | Rotateq, Gardasil 9, Vaxneuvance |
| Genentech USA, INC. | $43.87 | 2021-2022 | |
| Sanofi Pasteur INC. | $42.04 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.65 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $28.28 | 2019 | |
| Vertical Pharmaceuticals, LLC | $24.12 | 2019 | |
| Acadia Pharmaceuticals INC | $19.09 | 2025 | Daybue |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $18.45 | 2024 | |
| Biomarin Pharmaceutical INC. | $16.84 | 2023 | Voxzogo 1.2mg |
| Adlon Therapeutics L.P. | $16.26 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.03 | 2023 | |
| Tris Pharma INC | $15.96 | 2021 | |
| Glaxosmithkline, LLC. | $14.57 | 2019 | |
| Kaleo, INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Byrne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.